Sign inJoin waitlistJoin the waitlist

NM

Nataliya Mar

Associate Professor — Division of Hematology and Oncology, Medicine · University of California

Credentials: · · ·

History

University of California
Present

Medical Oncology
2012–2014
Internal Medicine
Lenox Hill Hospital-Northwell Health
2009–2012
SUNY Upstate Medical University Coll of Med
2005–2009

Research

Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
New England Journal of Medicine · 2024 · 923 citations
Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
Journal of Clinical Oncology · 2023 · 187 citations
Targeting HER2 in the treatment of non-small cell lung cancer
Review · Lung Cancer · 2015 · First of 3 authors · Corresponding · 80 citations

AK
Arash Kalebasty
9 papers
Steven Seyedin
8 papers
DK
Dalia Kaakour
6 papers · 6 as a resident
Armon Azizi
5 papers · 4 as a resident
David Benjamin
5 papers · 1 as a fellow
MD
Michael Daneshvar
5 papers
SD
Sami Dwabe
5 papers · 5 as a fellow
Shilpa Gupta
5 papers
Alexandra Drakaki
4 papers
Edward Uchio
4 papers
GH
Garrett Harada
4 papers · 4 as a resident
JV
James Vredenburgh
4 papers

Clinical trials

Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence
Principal investigator · Recruiting · Phase 2
University of California, Irvine
2024–2026
mpMRI Compared to Diagnostic TURBT in Patients With Suspected Muscle-Invasive Bladder Cancer
Principal investigator · Recruiting
University of California, Irvine
2024–2030
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2025–2033
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2025–2030